T Walley

4.3k total citations · 1 hit paper
82 papers, 3.0k citations indexed

About

T Walley is a scholar working on Economics and Econometrics, General Health Professions and Public Health, Environmental and Occupational Health. According to data from OpenAlex, T Walley has authored 82 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Economics and Econometrics, 22 papers in General Health Professions and 11 papers in Public Health, Environmental and Occupational Health. Recurrent topics in T Walley's work include Health Systems, Economic Evaluations, Quality of Life (19 papers), Primary Care and Health Outcomes (10 papers) and Pharmaceutical Economics and Policy (10 papers). T Walley is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (19 papers), Primary Care and Health Outcomes (10 papers) and Pharmaceutical Economics and Policy (10 papers). T Walley collaborates with scholars based in United Kingdom, Saudi Arabia and Italy. T Walley's co-authors include Alan Haycox, Y Dündar, A Bagust, Rumona Dickson, Angela Boland, C McLeod, Stuart Barton, Ruaraidh Hill, Rubén Mújica-Mota and Majid Davari and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Hypertension.

In The Last Decade

T Walley

81 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The UK General Practice Research Database

1997 548 citations T Walley et al. The Lancet profile →

Peers

Countries citing papers authored by T Walley

Since Specialization

Citations

This map shows the geographic impact of T Walley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T Walley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T Walley more than expected).

Fields of papers citing papers by T Walley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T Walley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T Walley. The network helps show where T Walley may publish in the future.

Co-authorship network of co-authors of T Walley

This figure shows the co-authorship network connecting the top 25 collaborators of T Walley. A scholar is included among the top collaborators of T Walley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T Walley. T Walley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. 2011 ·Health Technology Assessment ·Nigel Fleeman, C Martin Saborido, Katherine Payne, Angela Boland, (unknown), Y Dündar, Ana Fernández‐Santander, Sacha J. Howell, William G. Newman, J Oyee, T Walley	41
2	The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation 2010 ·Health Technology Assessment ·Nigel Fleeman, C McLeod, A Bagust, Sophie Beale, Angela Boland, Y Dündar, A. Jørgensen, Katherine Payne, Munir Pirmohamed, Sudeep Pushpakom, T Walley, (unknown), Rumona Dickson	53
3	Medicines Regulation and Health Technology Assessment 2010 ·Clinical Pharmacology & Therapeutics ·A Breckenridge, (unknown), T Walley	12
4	The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation 2008 ·SHILAP Revista de lepidopterología ·Jo Hockenhull, Kerry Dwan, Angela Boland, (unknown), A Bagust, Y Dündar, Carrol Gamble, C McLeod, T Walley, Rumona Dickson	5
5	Developments for funding clinical research in the UK 2008 ·The Lancet ·T Walley, Rajesh V. Thakker	3
6	Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation 2007 ·Health Technology Assessment ·Y Dündar, A Bagust, Rumona Dickson, Susanna Dodd, (unknown), (unknown), Ruaraidh Hill, C McLeod, T Walley	16
7	Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation 2007 ·Health Technology Assessment ·C McLeod, A Bagust, Angela Boland, Pierre Dagenais, Rumona Dickson, Y Dündar, Ruaraidh Hill, Alexis Jones, Rubén Mújica-Mota, T Walley	141
8	Health Care Challenges in Iran 2005 ·SHILAP Revista de lepidopterología ·Majid Davari, Alan Haycox, T Walley	6
9	Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003 2005 ·British Journal of Clinical Pharmacology ·T Walley, Pietro Folino-Gallo, P. Stephens, Éric Van Ganse, (unknown)	142
10	Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe 2004 ·European Journal of Clinical Pharmacology ·T Walley, Pietro Folino-Gallo, Ulrich Schwabe, Éric Van Ganse, P. Stephens	16
11	Trends in primary care antibiotic prescribing in England 1994–1998 2001 ·Pharmacoepidemiology and Drug Safety ·(unknown), T Walley	12
12	Lifestyle medicines 2000 ·BMJ ·(unknown), T Walley, B New	32
13	Average daily quantities: a tool for measuring prescribing volume in England 2000 ·Pharmacoepidemiology and Drug Safety ·T Walley, David J. Roberts	28
14	Therapeutic substitution and therapeutic conservatism as cost-containment strategies in primary care: a study of fundholders and non-fundholders. 1999 ·PubMed ·Robert Wilson, Juanita Hatcher, Stuart Barton, T Walley	12
15	Integrating clinical pharmacology in a new problem based medical undergraduate curriculum 1997 ·British Journal of Clinical Pharmacology ·(unknown), T Walley, John Bligh	4
16	Pharmacoeconomics: integrating economic evaluation into clinical trials 1997 ·British Journal of Clinical Pharmacology ·Alan Haycox, Michael Drummond, T Walley	16
17	Pharmacoeconomics: basic concepts and terminology 1997 ·British Journal of Clinical Pharmacology ·T Walley, Alan Haycox	40
18	A purchaser perspective of managing new drugs: interferon beta as a case study 1995 ·BMJ ·T Walley, Stuart Barton	16
19	Health Economics in Primary Care in the UK 1993 ·PharmacoEconomics ·T Walley, Rhiannon Tudor Edwards	14
20	The effects of intravenous and oral nifedipine on ex vivo platelet function 1989 ·European Journal of Clinical Pharmacology ·T Walley, KL Woods, David Barnett	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact